NCT05199142 - A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions

Cognitive Decline

Interventions

DRUG

SDI-118

SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.

DRUG

Placebo

The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.

Trial Locations (2)

60528

University Hospital Frankfurt, Frankfurt am Main

EC2Y 8EA

St Pancras Clinical Research, London